ABSTRACT
The incidence of thrombocytopenia was assessed in a retrospective review of 174 consecutive patients undergoing coronary stent implementation with administration of abciximab and either ticlopidine or clopidogrel. Sixteen of the patients (9.2%) developed thrombocytopenia with four (2.3%) cases rated as severe. Reaction onset was less than 24 hours in all but one patient. Patients who had received clopidogrel loading dose (300 mg) with abciximab had a higher rate than with abciximab alone (24% vs 2.5 % to 5.2%).
